Wedbush reiterates its Outperform rating and $6 price target on Celidex Therapeutics CLDX as it believes the primary value drivers for the company are CDX-011 n breast cancer and rindopepimut in glioblastoma.
Wedbush notes, "Celldex announced complete accrual of CDX-011 Phase 2b "EMERGE" study in women with GPNMB expressing advanced breast cancer; data anticipated H1:12. The Phase IIb results will guide design of a pivotal study in a patient population with an unmet medical need—in our opinion, triple-negative breast cancer patients. ...Earlier this month Celldex initiated its Phase III “ACT IV” study of rindopepimut in patients with EGFRvIII positive glioblastoma. The study protocol will include a randomized KLH-control, double-blind study of 374 patients at >150 clinical sites internationally."
CLDX closed at 2.65 per share on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in